Stolper Co lessened its holdings in UnitedHealth Group Inc (NYSE:UNH) by 6.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 17,492 shares of the healthcare conglomerate’s stock after selling 1,296 shares during the period. UnitedHealth Group accounts for approximately 3.4% of Stolper Co’s portfolio, making the stock its 5th largest position. Stolper Co’s holdings in UnitedHealth Group were worth $5,159,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of UNH. Ellis Investment Partners LLC increased its holdings in shares of UnitedHealth Group by 6.6% during the first quarter. Ellis Investment Partners LLC now owns 568 shares of the healthcare conglomerate’s stock valued at $134,000 after acquiring an additional 35 shares in the last quarter. Sound View Wealth Advisors Group LLC boosted its position in UnitedHealth Group by 1.1% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 3,411 shares of the healthcare conglomerate’s stock worth $851,000 after purchasing an additional 37 shares in the last quarter. Vista Investment Management boosted its position in UnitedHealth Group by 0.9% in the 1st quarter. Vista Investment Management now owns 4,082 shares of the healthcare conglomerate’s stock worth $1,018,000 after purchasing an additional 38 shares in the last quarter. Arkadios Wealth Advisors boosted its position in UnitedHealth Group by 1.9% in the 1st quarter. Arkadios Wealth Advisors now owns 2,110 shares of the healthcare conglomerate’s stock worth $526,000 after purchasing an additional 39 shares in the last quarter. Finally, Windsor Group LTD boosted its position in UnitedHealth Group by 0.9% in the 2nd quarter. Windsor Group LTD now owns 4,497 shares of the healthcare conglomerate’s stock worth $1,326,000 after purchasing an additional 39 shares in the last quarter. 86.59% of the stock is owned by institutional investors.
In related news, Director Stephen J. Hemsley sold 45,637 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $289.11, for a total value of $13,194,113.07. Following the sale, the director now directly owns 1,013,122 shares in the company, valued at approximately $292,903,701.42. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.80% of the stock is owned by company insiders.
UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings results on Wednesday, April 15th. The healthcare conglomerate reported $3.72 earnings per share for the quarter, topping analysts’ consensus estimates of $3.63 by $0.09. The business had revenue of $64.40 billion for the quarter, compared to analysts’ expectations of $64.25 billion. UnitedHealth Group had a return on equity of 24.86% and a net margin of 5.59%. The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the firm earned $3.73 EPS. As a group, sell-side analysts forecast that UnitedHealth Group Inc will post 16.27 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Monday, June 22nd were given a $1.25 dividend. This is a boost from UnitedHealth Group’s previous quarterly dividend of $1.08. This represents a $5.00 annualized dividend and a yield of 1.71%. The ex-dividend date was Friday, June 19th. UnitedHealth Group’s dividend payout ratio (DPR) is currently 33.09%.
Several research firms have commented on UNH. Deutsche Bank lowered their price objective on UnitedHealth Group from $308.00 to $293.00 and set a “buy” rating on the stock in a research report on Thursday, April 16th. Credit Suisse Group reaffirmed a “buy” rating on shares of UnitedHealth Group in a research note on Wednesday, May 27th. SVB Leerink started coverage on UnitedHealth Group in a report on Wednesday, July 1st. They set an “outperform” rating and a $360.00 target price for the company. Morgan Stanley lifted their price objective on UnitedHealth Group from $289.00 to $371.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, ValuEngine cut UnitedHealth Group from a “hold” rating to a “sell” rating in a research note on Thursday, July 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-two have issued a buy rating to the stock. UnitedHealth Group presently has an average rating of “Buy” and a consensus price target of $325.92.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
See Also: Range Trading
Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Inc (NYSE:UNH).
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.